Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal

The Wall Street JournalView source article

Part of story

Roche licenses obesity drug from China's Rona Therapeutics for up to $1.2 billion

Roche entered a licensing agreement worth up to $1.16 billion with Chinese biotech Rona Therapeutics for an investigational RNAi-based obesity drug candidate, marking Roche's seventh China deal this year.

Oct 13, 20263 sources

Roche licenses obesity drug from China's Rona Therapeutics for up to $1.2 billion

Other sources for this story

Reuters

Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics | Reuters

Endpoints

Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal

Part of story

Roche licenses obesity drug from China's Rona Therapeutics for up to $1.2 billion

Other sources for this story

Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics | Reuters

Roche's seventh China deal this year is a $1.2B obesity pact with an RNAi biotech

Roche Licenses Obesity Therapy From China’s Rona in Up to $1.2 Billion Deal

Part of story

Roche licenses obesity drug from China's Rona Therapeutics for up to $1.2 billion

Other sources for this story

Roche strikes obesity drug licensing deal worth up to $1.16 bln with Chinese Rona Therapeutics | Reuters

Roche's seventh China deal this year is a $1.2B obesity pact with an RNAi biotech